Cone Health Women's Hospital

Viz.ai® Announces Three New Studies Supporting Viz HCM™ Module for the Detection and Management of Suspected Hypertrophic Cardiomyopathy

Retrieved on: 
Wednesday, April 3, 2024
Health, Technology, Hospitals, Health Technology, Software, Artificial Intelligence, Cardiology, Deep learning, FACC, Harvard Medical School, Machine learning, Cone Health Women's Hospital, PPV, Innovation, Algorithm, Artificiality, Assistant, Disease, Associate, Patient, Atlantic Health System, Triage, Salem Hospital, AI, Viz, American College, Massachusetts General Hospital, HCM, Hospital, Hypertrophic cardiomyopathy, Senior counsel, Sports cardiology, Hypertrophy, Medical director, Probability, FDA, ACC, ECG, Mass, Medical imaging

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in cardiology care.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in cardiology care.
  • The Viz HCM module is the first and only AI algorithm cleared by the FDA for HCM.
  • The study found that Viz HCM performance in suspected HCM detection was consistent across various racial backgrounds with a sensitivity of 68.4% and specificity of 99.1%.
  • This validates the effectiveness of relevance score sorting for prioritizing higher probability HCM-positive patients identified by deep-learning algorithms analyzing ECG data.

AMERICAN SKIN ASSOCIATION ANNOUNCES NEW BOARD MEMBER JOSEPH F. MEROLA, MD, MMSc, FAAD, FACR

Retrieved on: 
Thursday, April 4, 2024
Cone Health Women's Hospital, Internal medicine, Patient, Skin, FAAD, Connective tissue, DSM-IV codes, Education, ASA, MDS, MMSc, Mass, Harvard Medical School, Associate, National Psoriasis Foundation, Psoriatic arthritis, Hospital, Public health, Atopic dermatitis, Dermatomyositis, Lupus, American Academy, Assessment, Management

NEW YORK, April 4, 2024 /PRNewswire/ -- American Skin Association (ASA) announced today that Joseph F. Merola, MD, MMSc, FAAD, FACR, will join its Board of Directors.

Key Points: 
  • NEW YORK, April 4, 2024 /PRNewswire/ -- American Skin Association (ASA) announced today that Joseph F. Merola, MD, MMSc, FAAD, FACR, will join its Board of Directors.
  • Distinguished Chair in Dermatology and is Professor at the Peter O'Donnell Jr. School of Public Health.
  • "We are proud to announce the addition of Dr. Joseph Merola to ASA's Board of Directors.
  • He was recently elected to the Board of the American Academy of Dermatology.

BayCare's St. Joseph's Women's Hospital Achieves Level IV Maternal Care Certification from The Joint Commission

Retrieved on: 
Thursday, March 21, 2024
Consensus, Mother, RN, Disease, Certification, Culture, Cone Health Women's Hospital, Level, Central Florida, Woman, Joint Commission, MLC, Mental, Partnership, Education, Verification, DNP, Patient, Mental health, Mortality, Anesthesiology, University, MBA, American College, OCC, Hospital, ACOG, Health, Nursing

TAMPA, Fla., March 21, 2024 /PRNewswire/ -- BayCare, the leading health care system in West Central Florida, today announced that St. Joseph's Women's Hospital has attained the highest level of certification in Maternal Care by The Joint Commission, the nation's oldest health care accrediting organization.

Key Points: 
  • TAMPA, Fla., March 21, 2024 /PRNewswire/ -- BayCare, the leading health care system in West Central Florida, today announced that St. Joseph's Women's Hospital has attained the highest level of certification in Maternal Care by The Joint Commission, the nation's oldest health care accrediting organization.
  • As a Level IV maternal care verified facility, St. Joseph's Women's Hospital is recognized for its commitment to providing exceptional maternal healthcare services.
  • "The Joint Commission commends St. Joseph's Women's Hospital for being named a Level IV maternal care verified facility and for its efforts to standardize maternal care and reduce maternal morbidity and mortality," says Ken Grubbs, DNP, MBA, RN, executive vice president of Accreditation and Certification Operations and chief nursing officer, The Joint Commission.
  • "The Maternal Levels of Care Verification program will help St. Joseph's Women's Hospital strengthen regionalized care for mothers and babies in its community."

Ibex Presents New Data from Multiple Studies Showcasing Accuracy of AI in Prostate, Breast and Gastric Cancer Diagnosis

Retrieved on: 
Thursday, March 21, 2024
Diagnosis, Champalimaud Foundation, Cone Health Women's Hospital, PPV, Glomus tumor, Adenoma, Overdiagnosis, Incidence, Research, Cancer, Hospital, UPMC, Breast, Marie Cassidy, AI, University, Laboratory, MD, Oncology, Medicine, USCAP, OSU, Dysplasia, Brigham and Women's Hospital, Breast cancer, Ohio State University, Pathology, Champalimaud, Stomach, Artificial intelligence, Annual general meeting, NPV, Medical imaging

BOSTON, March 21, 2024 /PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced excellent results across multiple clinical studies conducted with the University of Pittsburgh Medical Center (UPMC), Brigham and Women's Hospital, Champalimaud Foundation and Ohio State University (OSU). These studies, highlighting the value of Ibex's AI-powered cancer diagnostics solutions in both diagnostic quality and efficiency, will be presented next week at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting.

Key Points: 
  • Brigham and Women's Hospital and Champalimaud Foundation research shows high accuracy levels of Galen Breast in identifying microinvasive carcinoma of the breast.
  • Ohio State University Wexner Medical Center studies show high accuracy for Galen Breast and Galen Gastric in detecting and distinguishing between different types of cancer and in identifying multiple important pathologies.
  • In addition, researchers from OSU Wexner Medical Center will present studies validating Galen Breast's performance in detecting different types of breast cancer.
  • Ibex will be showcasing these findings at the USCAP Annual Meeting taking place in Baltimore, Maryland, between March 23 to 28, at booth number 755.

Advancing Skin Cancer Detection: American Academy of Dermatology Journal Publishes DermaSensor's Breakthrough Melanoma Detection Results From A Major, Multicenter Trial

Retrieved on: 
Wednesday, February 28, 2024
Software, Research, Hardware, Pharmaceutical, Oncology, Technology, Medical Devices, Health Technology, Clinical Trials, Science, Medical Supplies, Practice Management, Health, VA Boston Healthcare System, Skin cancer, Melanoma, NPV, Principal, Physician, FDA, Integral, Hospital, Assessment, Skin, Negative, Patient, Journal, Cone Health Women's Hospital, Harvard Medical School, American Academy, Medical device

In addition, the Negative Predictive Value (NPV) of 98.1% (95% CI, 91.8%-99.6%) indicates a high level of reliability for a negative device result of “Monitor”.

Key Points: 
  • In addition, the Negative Predictive Value (NPV) of 98.1% (95% CI, 91.8%-99.6%) indicates a high level of reliability for a negative device result of “Monitor”.
  • For a positive device result of “Investigate Further”, a 1-10 score is also provided to indicate the degree of similarity to malignant lesions.
  • The study found that the likelihood of melanoma for these positive results ranged from 10.3% for low scores (i.e., 1-3) to 47.4% for high scores (i.e., 8-10).
  • This automated, objective device can help in the fight against skin cancer, and the DermaSensor team is dedicated to making a meaningful contribution to its detection and prevention."

THE PROSTATE CANCER FOUNDATION AND THE AMERICAN CANCER SOCIETY ANNOUNCE FIRST ACS-PCF YOUNG INVESTIGATOR AWARD

Retrieved on: 
Thursday, February 22, 2024
Prostate Cancer Foundation, University College London, American Cancer Society, Doctor of Philosophy, Prostate cancer, PCF, PARP, ACS, Hospital, Geography, Mentorship, Organization, Patient, Health equity, Cone Health Women's Hospital, Research, Cancer, Partnership

LOS ANGELES, Feb. 22, 2024 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) and the American Cancer Society (ACS) today announced the ACS-PCF Young Investigator Award totaling $225,000 over three years to support a novel health equity research project that aims to reduce disparities in access to modern prostate cancer care in rural settings.

Key Points: 
  • LOS ANGELES, Feb. 22, 2024 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) and the American Cancer Society (ACS) today announced the ACS-PCF Young Investigator Award totaling $225,000 over three years to support a novel health equity research project that aims to reduce disparities in access to modern prostate cancer care in rural settings.
  • One in eight men in the U.S. will be diagnosed with prostate cancer in his lifetime, and it is the most commonly diagnosed non-skin cancer in men1.
  • "The Prostate Cancer Foundation has been funding research to understand and address prostate cancer disparities for more than 30 years," said Howard R. Soule, PhD, Executive Vice President and Chief Science Officer, PCF.
  • "We are thrilled to have Dr. Cole as our ACS-PCF Young Investigator," said William Dahut, MD, Chief Scientific Officer, American Cancer Society.

Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments

Retrieved on: 
Thursday, February 15, 2024
Neoplasm, Doctor of Philosophy, Immunotherapy, SCCA, News, Pharmaceutics, Destiny, PR, Optimism, Poster, Anal cancer, Pancreatic cancer, Anal, CEACAM6, Brigham and Women's Hospital, Bristol Myers Squibb, Therapy, Immune system, Pelareorep, International, Breast cancer, Fast track (FDA), Serology, AIO, Hospital, Hope, Principal investigator, HGG, Conference, Safety, Biomarker, Tumor microenvironment, Patent, Clinical trial, Survival, Harvard Medical School, Acute lymphoblastic leukemia, Injection, MSI, MD, BioNTech, FDA, TSX, Cancer, Entrepreneurship, Prevalence, American depositary receipt, Anal canal, Patient, Cone Health Women's Hospital, ONC, Pharmaceutical industry

According to the American Association for Cancer Research "Cancer immunotherapeutics work by unleashing the power of a patient's immune system to fight cancer and, over the last decade, have emerged as one of the most exciting new approaches to cancer treatment."

Key Points: 
  • According to the American Association for Cancer Research "Cancer immunotherapeutics work by unleashing the power of a patient's immune system to fight cancer and, over the last decade, have emerged as one of the most exciting new approaches to cancer treatment."
  • Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) is developing pelareorep, a unique immunotherapy with the power to awaken the immune system and unlock its antitumor potential.
  • It is committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
  • Bristol-Myers Squibb and Fate Therapeutics are some of the other key patent filers in cancer immunotherapy."

Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenues

Retrieved on: 
Wednesday, January 3, 2024
Category 1, Conference, Cleveland Clinic, Hospital, Sale, Johns Hopkins Hospital, Cone Health Women's Hospital, Prostate cancer, Level 1, Monroe Dunaway Anderson, Investment, TSX, News, Prostate, Pharmaceutical industry

Profound anticipates total revenues for the fourth quarter of 2023 to be in the approximate range of $1.9 million to $2.0 million, with the full amount coming from recurring revenue, which consists of the sale of TULSA-PRO® consumables, lease of medical devices, procedures and services associated with extended warranties.

Key Points: 
  • Profound anticipates total revenues for the fourth quarter of 2023 to be in the approximate range of $1.9 million to $2.0 million, with the full amount coming from recurring revenue, which consists of the sale of TULSA-PRO® consumables, lease of medical devices, procedures and services associated with extended warranties.
  • This represents recurring revenue growth of between 51% and 59% year-over-year, and between 10% and 16% sequentially over the 2023 third quarter.
  • For the full year 2023, Profound anticipates total revenues to be in the approximate range of $7.1 million to $7.2 million.
  • These figures are preliminary and unaudited, and actual revenues may differ.

Elsevier Health Partners with OpenEvidence to Deliver Trusted Evidence-Based Clinical Content Powered by Responsible AI to Support Physicians' Clinical Decisions

Retrieved on: 
Wednesday, November 15, 2023
Hospital, Partnership, Book, Physician, Research, Cone Health Women's Hospital, MD, Doctor of Philosophy, AI, Artificial intelligence, Machine learning, Face, Harvard Medical School, Elsevier, Medical device

By combining Elsevier's vast corpus of trusted medical information with advanced AI technology, ClinicalKey AI can help physicians access accurate evidence-based information at the point of care.

Key Points: 
  • By combining Elsevier's vast corpus of trusted medical information with advanced AI technology, ClinicalKey AI can help physicians access accurate evidence-based information at the point of care.
  • Jan Herzhoff, PhD, President, Elsevier Health said: "We believe ClinicalKey AI can be a game-changer for physicians.
  • OpenEvidence's AI will power Elsevier's trusted medical content in the places and at the moments when physicians need it most."
  • ClinicalKey AI will be available for early access starting in November 2023 with a full-scale US launch starting in early 2024.

Largest study to date of high-dose methotrexate associated acute kidney injury supports the use of Voraxaze® (glucarpidase)

Retrieved on: 
Monday, December 11, 2023
MMSc, Hospital, AKI, Division, Cone Health Women's Hospital, Mortality, Neutropenia, SCR, Society, Odds ratio, Observational study, Acute kidney injury, Transaminase, MPH, Patient, Harvard Medical School, Nursing

West Conshohocken, PA, Dec. 11, 2023 (GLOBE NEWSWIRE) -- BTG Pharmaceuticals, a SERB company, announces the presentation of the largest study to date of patients with high-dose methotrexate (HDMTX) associated Acute Kidney Injury (AKI) treated with and without glucarpidase.

Key Points: 
  • West Conshohocken, PA, Dec. 11, 2023 (GLOBE NEWSWIRE) -- BTG Pharmaceuticals, a SERB company, announces the presentation of the largest study to date of patients with high-dose methotrexate (HDMTX) associated Acute Kidney Injury (AKI) treated with and without glucarpidase.
  • Among the 708 patients with HDMTX-AKI, 209 (29.5%) were treated with glucarpidase and 499 (70.5%) were not.
  • Treatment with glucarpidase was associated with a 2.41-fold higher adjusted odds of kidney recovery at hospital discharge (95% CI, 1.33–4.37) compared to those not treated with glucarpidase.
  • “This is the largest study to date of HDMTX-AKI,” said study author Dr. Shruti Gupta, MD, MPH, Director of Onconephrology in the Division of Renal Medicine, Brigham and Women's Hospital.